Nuvalent, Inc.

Nuvalent, Inc. is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts. Founded in 2017 and listed on Nasdaq under ticker NUVL, it develops precisely targeted small-molecule therapies for cancer using structure-based drug design. Its pipeline focuses on kinase inhibitors for non-small cell lung cancer, including zidesamtinib (ROS1), neladalkib (ALK), and NVL-330 (HER2), along with earlier-stage programs.

In June 2026, GSK agreed to acquire Nuvalent for $10.6 billion in cash, subject to regulatory approvals and tender offer conditions, with expected closing in Q3 2026.

To provide comprehensive coverage, we aggregate data and news under the name Nuvalent, Inc., encompassing the following company names, divisions, and related entities:

NUVL and Nuvalent.

This list encompasses current and former names, alternate names, and key divisions associated with Nuvalent, Inc., ensuring you can easily find all relevant information under a single, unified profile.